Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Aug 1;102(3):633–638. doi: 10.1172/JCI3121

Mobilization of potent plasma bactericidal activity during systemic bacterial challenge. Role of group IIA phospholipase A2.

Y Weinrauch 1, C Abad 1, N S Liang 1, S F Lowry 1, J Weiss 1
PMCID: PMC508924  PMID: 9691100

Abstract

Extracellular mobilization of Group IIA 14-kD phospholipase A2 (PLA2) in glycogen-induced rabbit inflammatory peritoneal exudates is responsible for the potent bactericidal activity of the inflammatory fluid toward Staphylococcus aureus (1996. J. Clin. Invest. 97:250-257). Because similar levels of PLA2 are induced in plasma during systemic inflammation, we have tested whether this gives rise to plasma bactericidal activity not present in resting animals. Baboons were injected intravenously (i.v.) with a lethal dose of Escherichia coli and plasma or serum was collected before and at hourly intervals after injection. After infusion of bacteria, PLA2 levels in plasma and serum rose > 100-fold over 24 h to approximately 1 microg PLA2/ml. Serum collected at 24 h possessed potent bactericidal activity toward S. aureus, Streptococcus pyogenes, and encapsulated E. coli not exhibited by serum collected from unchallenged animals. Bactericidal activity toward S. aureus and S. pyogenes was nearly completely blocked by a monoclonal antibody to human Group IIA PLA2 and addition of purified human Group IIA PLA2 to prechallenge serum conferred potent antistaphylococcal and antistreptococcal activity equal to that of the 24 h post-challenge serum. PLA2-dependent bactericidal activity was enhanced approximately 10x by factor(s) present constitutively in serum or plasma. Bactericidal activity toward encapsulated E. coli was accompanied by extensive bacterial phospholipid degradation mediated, at least in part, by the mobilized Group IIA PLA2 but depended on the action of other bactericidal factors in the 24-h serum. These findings further demonstrate the contribution of Group IIA PLA2 to the antibacterial potency of biological fluids and suggest that mobilization of this enzyme during inflammation may play an important role in host defense against invading bacteria.

Full Text

The Full Text of this article is available as a PDF (205.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beckerdite-Quagliata S., Simberkoff M., Elsbach P. Effects of human and rabbit serum on viability, permeability, and envelope lipids of Serratia marcescens. Infect Immun. 1975 Apr;11(4):758–766. doi: 10.1128/iai.11.4.758-766.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chilton F. Would the real role(s) for secretory PLA2s please stand up. J Clin Invest. 1996 May 15;97(10):2161–2162. doi: 10.1172/JCI118654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Crowl R. M., Stoller T. J., Conroy R. R., Stoner C. R. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem. 1991 Feb 5;266(4):2647–2651. [PubMed] [Google Scholar]
  4. Dennis E. A. The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem Sci. 1997 Jan;22(1):1–2. doi: 10.1016/s0968-0004(96)20031-3. [DOI] [PubMed] [Google Scholar]
  5. Donaldson D. M., Tew J. G. beta-Lysin of platelet origin. Bacteriol Rev. 1977 Jun;41(2):501–513. doi: 10.1128/br.41.2.501-513.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Elsbach P., Weiss J., Levy O. Integration of antimicrobial host defenses: role of the bactericidal/permeability-increasing protein. Trends Microbiol. 1994 Sep;2(9):324–328. doi: 10.1016/0966-842x(94)90449-9. [DOI] [PubMed] [Google Scholar]
  7. Elsbach P., Weiss J. Utilization of labeled Escherichia coli as phospholipase substrate. Methods Enzymol. 1991;197:24–31. doi: 10.1016/0076-6879(91)97130-q. [DOI] [PubMed] [Google Scholar]
  8. Jansen P. M., Boermeester M. A., Fischer E., de Jong I. W., van der Poll T., Moldawer L. L., Hack C. E., Lowry S. F. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia. Blood. 1995 Aug 1;86(3):1027–1034. [PubMed] [Google Scholar]
  9. Kudo I., Murakami M., Hara S., Inoue K. Mammalian non-pancreatic phospholipases A2. Biochim Biophys Acta. 1993 Nov 3;1170(3):217–231. doi: 10.1016/0005-2760(93)90003-r. [DOI] [PubMed] [Google Scholar]
  10. Levy O., Ooi C. E., Weiss J., Lehrer R. I., Elsbach P. Individual and synergistic effects of rabbit granulocyte proteins on Escherichia coli. J Clin Invest. 1994 Aug;94(2):672–682. doi: 10.1172/JCI117384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Madsen L. M., Inada M., Weiss J. Determinants of activation by complement of group II phospholipase A2 acting against Escherichia coli. Infect Immun. 1996 Jul;64(7):2425–2430. doi: 10.1128/iai.64.7.2425-2430.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Murakami M., Nakatani Y., Kudo I. Type II secretory phospholipase A2 associated with cell surfaces via C-terminal heparin-binding lysine residues augments stimulus-initiated delayed prostaglandin generation. J Biol Chem. 1996 Nov 22;271(47):30041–30051. doi: 10.1074/jbc.271.47.30041. [DOI] [PubMed] [Google Scholar]
  13. Nevalainen T. J., Aho H. J., Peuravuori H. Secretion of group 2 phospholipase A2 by lacrimal glands. Invest Ophthalmol Vis Sci. 1994 Feb;35(2):417–421. [PubMed] [Google Scholar]
  14. Nevalainen T. J., Meri K. M., Niemi M. Synovial-type (group II) phospholipase A2 human seminal plasma. Andrologia. 1993 Nov-Dec;25(6):355–358. doi: 10.1111/j.1439-0272.1993.tb02742.x. [DOI] [PubMed] [Google Scholar]
  15. Schevitz R. W., Bach N. J., Carlson D. G., Chirgadze N. Y., Clawson D. K., Dillard R. D., Draheim S. E., Hartley L. W., Jones N. D., Mihelich E. D. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat Struct Biol. 1995 Jun;2(6):458–465. doi: 10.1038/nsb0695-458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Sternberg N. L., Maurer R. Bacteriophage-mediated generalized transduction in Escherichia coli and Salmonella typhimurium. Methods Enzymol. 1991;204:18–43. doi: 10.1016/0076-6879(91)04004-8. [DOI] [PubMed] [Google Scholar]
  17. Stoner C. R., Reik L. M., Donohue M., Levin W., Crowl R. M. Human group II phospholipase A2. Characterization of monoclonal antibodies and immunochemical quantitation of the protein in synovial fluid. J Immunol Methods. 1991 Dec 15;145(1-2):127–136. doi: 10.1016/0022-1759(91)90318-a. [DOI] [PubMed] [Google Scholar]
  18. Tischfield J. A. A reassessment of the low molecular weight phospholipase A2 gene family in mammals. J Biol Chem. 1997 Jul 11;272(28):17247–17250. doi: 10.1074/jbc.272.28.17247. [DOI] [PubMed] [Google Scholar]
  19. Weinrauch Y., Elsbach P., Madsen L. M., Foreman A., Weiss J. The potent anti-Staphylococcus aureus activity of a sterile rabbit inflammatory fluid is due to a 14-kD phospholipase A2. J Clin Invest. 1996 Jan 1;97(1):250–257. doi: 10.1172/JCI118399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Weinrauch Y., Foreman A., Shu C., Zarember K., Levy O., Elsbach P., Weiss J. Extracellular accumulation of potently microbicidal bactericidal/permeability-increasing protein and p15s in an evolving sterile rabbit peritoneal inflammatory exudate. J Clin Invest. 1995 Apr;95(4):1916–1924. doi: 10.1172/JCI117873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Weiss J., Inada M., Elsbach P., Crowl R. M. Structural determinants of the action against Escherichia coli of a human inflammatory fluid phospholipase A2 in concert with polymorphonuclear leukocytes. J Biol Chem. 1994 Oct 21;269(42):26331–26337. [PubMed] [Google Scholar]
  22. Weiss J., Wright G., Bekkers A. C., van den Bergh C. J., Verheij H. M. Conversion of pig pancreas phospholipase A2 by protein engineering into enzyme active against Escherichia coli treated with the bactericidal/permeability-increasing protein. J Biol Chem. 1991 Mar 5;266(7):4162–4167. [PubMed] [Google Scholar]
  23. Wright G. C., Weiss J., Kim K. S., Verheij H., Elsbach P. Bacterial phospholipid hydrolysis enhances the destruction of Escherichia coli ingested by rabbit neutrophils. Role of cellular and extracellular phospholipases. J Clin Invest. 1990 Jun;85(6):1925–1935. doi: 10.1172/JCI114655. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES